EP2378900A2

EP2378900A2 - Food supplements based on pantothenic acid

Info

Publication number: EP2378900A2
Application number: EP09832689A
Authority: EP
Inventors: Hans-Dieter Minge
Original assignee: Individual
Current assignee: Individual
Priority date: 2008-12-23
Filing date: 2009-12-22
Publication date: 2011-10-26
Also published as: US20110313041A1; WO2010072209A3; WO2010072209A2; DE102008064588A1

Abstract

The invention relates to a food supplement for alleviating metabolic deficiency and containing pantothenic acid (CoA), precursors thereof and/or salts thereof and also to a method for production thereof and to use thereof. Fields of application of the invention are the food industry and medicine. The invention is based on the surprising discovery that the uptake of pantothenic acid, pantothenic acid-CoA and/or derivatives thereof in a large amount has an advantageous effect on symptoms which are caused by metabolic deficiency. The core of the invention is that the uptake of a pantothenic acid-CoA equivalent from the diet must be not 10 mg per day, but more than 10³ times that, in order to supply the human body optimally. Surprisingly, it was likewise found that the cholinergic panthenol-CoA uptake reaction from food took place within the course of a few minutes. The food supplement according to the invention comprises 85-99% pantothenic acid, precursors thereof, derivatives thereof and/or salts thereof and optionally further additives.

Description

Nutritional supplement based on pantothenic acid

The invention relates to a dietary supplement for alleviating metabolic weakness comprising pantothenic acid (CoA) _1, its preforms and / or their salts and a process for its preparation and its use. Areas of application of the invention are the food industry and medicine.

State of the art

Metabolic weakness is often but often underestimated in the run-up to illnesses. It results in the development of a variety of symptoms of weakness, exhaustion, fatigue, listlessness, discomfort, in the broadest sense of sensitive mental problems, and can gradually lead to the development of diseases. All organs involved in the digestion are involved in energy production from the food.

If problems occur at this point, fatigue is often the result. However, in addition to organic causes, undersupply or overloading of the body can be the cause of metabolic weakness and associated diseases.

Reduced food intake, among other things, also causes the associated habit of preferring light, denatured, starchy food denatured on ingredients of the grain, inevitably deficits, without taking into account an increased demand for exercise.

In antiquity, the term melancholia refers to the condition of great sadness, melancholy, apathy. According to current understanding, this refers to depression or a chronic state of fatigue, a so-called chronic fatigue syndrome (CFS) with debilitating weakness, lethargy, memory difficulties, muscle weakness and gastric problems.

In contrast to the normal course from fatigue to recovery, from exhaustion to convalescence, this exhaustion is not reversible. Chronic Fatigue, CFS, shows metabolic performance weakness in the chronic-deficient state. A precursor to this is formed in the so-called burnout syndrome and is not uncommon in a chronic fatigue syndrome.

Problems with the gastrointestinal tract of the digestive system are frequently observed in the phenomenon of chronic fatigue syndrome (CFS), but this has never been considered as a possible cause. (9)

Chronic fatigue syndrome (CFS) is a physiological condition in which the patient feels completely exhausted without finding an obvious organic cause. Two of the most typical and debilitating symptoms of CFS are very poor condition and prolonged fatigue after exercise. Sometimes exhaustion is mainly mental and sometimes physical. A widespread hypothesis (A) is that the metabolism of people with CFS is normal, but fatigue and other symptoms are psychological factors. It is recognized that physical fatigue is a lack of energy, but mental fatigue is said to be a subjective sensation characterized by lack of motivation and caution. (11)

Abnormal fatigue is known as a pathological feature in many diseases, but CFS has no obvious organic cause. The impossible position of the ill, who are considered medically healthy and who are suspected of indulging in weakness, brings them to psychiatry with their depression, without being able to expect help there.

Chronic Fatigue Syndrome (CFS) is a multi-system disease that deprives its victims of their health and dignity. (11)

The disease can take years; while some patients recover afterward, others persist for a decade or more without significant recovery.

(12)

To date, neither the cause nor a satisfactory solution has been found for the treatment of metabolic weakness, in particular Chronic Fatigue Syndrome (CFS). The severity of exhaustion is biochemically as a specific change in

Function and condition of mitochondria detectable, being a mitochondrial

Dysfunction is effected. (11) As a cause of the states of weakness and

Fatigue is thought to be due to decreased mitochondrial energy production (12), with CFS being triggered by viral infections of the stomach. (6)

"An alternative hypothesis (B) is that there is a metabolic malfunction with the result that not enough energy is generated.

Thus, mitochondrial dysfunction will result in fatigue and may produce other symptoms of CFS. "(11)

In the case of the fatally exhausted Gulfwar veterans of the Iraq war of 1991, those who are still experiencing serious problems in the gastrointestinal tract in 2008 are documented, but not considered as the cause. (9)

Here, the step of energy production in mitochondria is of central importance. There is already a correlation between disorders in the mitochondria and the occurrence of disease symptoms in the prior art described (1). Especially in the education of CFS these disorders play a role. In this context, a specific diet containing various vitamins and minerals is recommended (2). Among them is also pantothenic acid. The use of pantothenic acid is also already suggested in US 5,360,821 in order to increase constitution and physical strength. Also in US 5,304,574 the addition of pantothenic acid in place of steroids is described to achieve this effect.

Keil (Diss.) Describes a connection between neurodegenerative diseases such as Alzheimer's or Parkinson's and mitochondrial disorders. The protective effect of certain substances for the mitochondria, as well as Gingko biloba extract, is illuminated. (3)

Object of the invention

The object of the invention is therefore to provide a means which against a

Metabolic weakness acts and corrects their symptoms. The object is solved by the claims 1, 2 10-13, 15, the dependent claims are preferred variants.

Essence of the invention

The invention is based on the surprising discovery of Mr. Hans Dieter Minge that the intake of pantothenic acid, pantothenic acid-CoA and / or its derivatives in large quantities beneficial effects on symptoms that are caused by metabolic weakness.

Pantothenic acid is a vital substance that occurs in plant and animal tissues to 50 to 95% in the form of coenzyme A and 4'-phosphopantetheine.

Pantothenic acid is called vitamin B ₅ , is water-soluble and is taken up with the food. Sources include vegetables, cereals, offal, meat and fish. Pantothenic acid in the form of coenzyme A (CoA) is involved in a variety of reactions in carbohydrate, fat and amino acid metabolism. CoA is 95% localized in the mitochondria at the ATP synthase. Pantothenic acid CoA is essential for the formation of acetylcholine. For intermediary metabolism, the most important ester of coenzyme A is activated acetic acid, the acetyl-CoA. Pantothenic acid CoA plays a central role in the modification of cellular proteins.

The use of pantothenic acid in the patent history is based on the recombination of CoA in the citrate cycle. This artifice potentiates CoA's multivariate existence in acetyl-CoA in carbohydrate, fat, amino acid, intermediary metabolism, and acetylcholine synthesis with minimal pantothenic acid intake. The uptake of pantothenic acid CoA in the metabolism should be done hours after the meal, after gastric passage, simultaneously with the food absorption in the small intestine. The daily requirement should be 10 mg. Pantothenic acid has no potential hazard nor are significant physiological reactions known in the art. (13) There is no evidence to suggest that pharmaceutical pantothenic acid is absorbed via oral delivery. Older authors report daily doses of 5-20 g without triggering reactions. The idea that pantothenic acid has no reaction potential has its basis here. (13) Currently, young people are taking 5-100 g of pantothenic acid capsules orally daily for weeks to treat acne. After incorporation of these amounts into the metabolism, smooth muscle CoA → acetyl-CoA → acetylcholine formation reactions should be expected. A small group of many who self-medicate reported side-effects such as occasional loose stool or gastric irritation, bloating or hunger sensations, and a strong appetite that could be mild acetylcholine-forming reactions. Only through the effects of the reaction sequence steps of the CoA is the pre-assumption existence of Pantothensäure- CoA presupposed. The pharmaceutical substance pantothenic acid, ph 7-8, is very probably deactivated in the stomach environment under ph 1-2. In general, unprotected oral pantothenic acid CoA uptake probably does not occur in the stomach.

The invention is based on the following surprising finding: After treatment of chronic fatigue, muscle weakness / muscle pain, weakness and respiratory depression with 140 mg of the acetylcholine steroid inhibitor neostigmine bromide, late at night, at breakfast, reactionless until then, 10 minutes after the first bite, adverse reactions began , weeping nose, watering eyes, urination, body cutting, which subsided after 15 min. Immediately thereafter, a reaction attempt on sublingual / buccally administered 2 g panthenol Tbl. Have been carried out. After 10 minutes, the same adverse reaction started with a similar duration. After their subsidence and continuation of breakfast with bread repeated 10 minutes later in the bladder, body and intestine, the same reactions in a shorter duration. Then again after sublingual / buccal administration of 2 g panthenol-tbl. the same reaction was delayed and took less time. The 140 mg of the acetylcholine steroid inhibitor neostigmine bromide was still effective after 6 reaction-free hours since ingestion. The hypothetical increase of acetylcholine after administration of pantothenic acid oenzyme A in the experiment:

Acetylcholine, the natural excitatory transmitter from the nerve to the muscle, acts on striped muscles in concentrations around 1 (T ⁶ g / I ₁ on smooth already at 1CT ¹⁶ g / I. (4) These "adverse" reactions are contractions of smooth muscle of lacrimal gland , Bladder, stomach, intestine, by acetylcholine suddenly formed there, exceeding the reaction threshold of 10 ^{~ 16} g acetylcholine per liter in the smooth muscle: a) within 10 minutes from gastric ingestion and at the end of reaction b) within 10 minutes from sublingual / buccal uptake of 2000 mg tbl panthenol, while existing acetylcholinesterase inhibition is below 140 mg neostromine bromide These sudden and unexpected adverse cholinergic reactions are also evidence of the ACH precursors CoA → cetyl-CoA via the acetylcholine augmentation reaction Food Pantothenic acid-CoA absorbs, depending on the food about 10 ³ -10 ⁴ times the amount of previous Assumptions. (13)

The essence of the invention is that the intake of a pantothenic acid -CoA equivalent from the diet must not be 10 mg per day, but more than 10 ³ times to provide the human organism optimal. Also surprising was the finding that the cholinergic panthenol-CoA uptake reaction from food occurred within a few minutes. It is therefore thought that pantothenic acid CoA is absorbed immediately via the mucous membranes and / or in the stomach, enters mitochondria and becomes effective in the citrate cycle. The enormous mismatch between minimal availability of pantothenic acid-CoA uptake and the most diverse needs for CoA in the acetyl-CoA pathway of the citrate cycle has been bridged by the construction of a recombination of CoA.

Really, Coenzyme A is changing from the role of the regenerating catalyst to the consumption factor, which, as a key factor, acts to mitigate response in mitochondria with low availability. The metabolic efficiency of the Organism depends on the mass of the available pantothenic acid CoA depot in the mitochondrial pool.

Muscle weakness and pain, weakness, respiratory depression, mental fatigue and gastric problems have been mainly treated with pantothenic acid-CoA, buk, vitamins and amino acids.

After improvement and discontinuation of the treatment, however, the symptoms returned after a short interval. Ultimately, the problems could be reduced and canceled under re-treatment. Only with the normalization of the function of the digestive factor, the uptake of pantothenic acid CoA from food in the stomach could be fully restored and the treatment was dispensable.

New is the recording

- the pantothenic acid from the stomach,

pantothenic acid and the acetylcholine-forming reaction within 10-15 minutes,

- pantothenic acid from food at about 10-100 g / day,

- pantothenic acid in an unknown way.

It is also new that disorders of the stomach hinder or reduce pantothenic acid intake and the existence of a depot potential of a few kilograms of pantothenic acid in the form of CoA in the mitochondria, in the tissue, in the muscles, which feeds the metabolic performance and thus the metabolic performance depends on availability of pantothenic acid → CoA. The pantothenic acid → CoA represents a consumption factor; their lack of availability as a key factor limits and depletes actions and responses. This is reflected in the phenomena of changing mental and physical life and health, in emotion, sexuality, creativity, memory, activity, movement, work, endurance, fatigue, recovery, exhaustion, illness, convalescence, infirmity, variants of metabolic capacity.

In daily life, fatigues the strength and exhaustion from meal to meal. The lesson is that food and pantothenic acid is absorbed in the small intestine after digestion in the stomach, the time interval is about 3 hours. However, a 15-minute meal break is enough to be productive again for 3 to 4 hours. Except for and before conventional digestion, apparently, the uptake of CoA agent takes place, primarily feeding that branch of metabolic activity that controls the nervous activity of emotion, sexuality, creativity, memory, activity, movement, work, and endurance.

This branch of nerve activity control "depletes" most of the CoA → acetyl CoA agent in mitochondria, which undergoes initial limitations in deficiency: within 15 minutes, the stomach of food takes pantothenic acid CoA → acetyl CoA into the mitochondria pool, Occasionally acetylcholine excess reactions occur after rich meals and appear as short-term watery eyes and a weeping nose.

To maintain or restore stable metabolic performance, an agent containing pantothenic acid CoA is provided. Preferably, this agent contains large amounts of pantothenic acid, pantothenic acid CoA or their preforms, more preferably in a daily dose of 10-100g. The invention also relates to a method for maintaining and improving metabolic performance, which is characterized in that large amounts of pantothenic acid, pantothenic acid-CoA or their preforms are taken.

Balancing the lack of CoA in mitochondrial dysfunction by adding pantothenic acid CoA improves the CoA → Acetyl-CoA balance in tissues and muscles, restores energy metabolism and / or supplements a lack of intake of pantothenic acid CoA from the diet via the stomach ,

Disturbed gastric function and / or depletion of mitochondrial reserves in myasthenia, autism, chronic fatigue syndrome is shown by the fading of yellow urine. Successful intake of pantothenic acid CoA intensifies the yellowing. The current optimum, the proof of success for the pantothenic acid-CoA treatment, is reached when harmless acetylcholine excess reactions occur in the bladder, stomach or intestine. Diseases of the stomach and digestive tract generally impair the uptake of all dietary agents. In addition to pantothenic acid CoA, the necessary deficiency compensation of amino acids, vitamins, etc. is also supported by coupled supply of these substances. Also proposed is the complementary administration of gingko preparations

Types of administration for the administration of pantothenic acid, pantothenic CoA or precursors thereof, optionally in combination with vitamins, amino acids, fatty acids, phospholipids, coenzymes, trace elements, bioactive substances, minerals and / or gingko are:

a) For the immediate need for weakness-fatigue:

Contact with the oral mucosa, preparation as Priem, chewing lozenge, Kaugelee, and / or insert; b) via contact in the small intestine after protected gastric passage as a gastric juice resistant preparation, in size from small grained to capsule, dragee, for example by inclusion in a gel, in pudding, in aqueous carriers and comparable suitable forms, even with a variable dissolution behavior; c) via skin contact from pantothenic acid-containing media, carrier films, implants, ointments, baths, etc. d) anal, for example as a suppository, u. ä.

In the US, autistic children often suffer from gastric problems and chronic diarrhea. As a result of the damage to the digestive tract, the pantothenic acid-CoA uptake function of the stomach is disturbed from food, with the consequence of chronic metabolic performance weakness, here autism. The low availability of pantothenic acid CoA, acetyl-CoA, acetylcholine chain hits children in the most sensitive and needy period of their mental development. The causative agent of the damage to the stomach that leads to this disease is unknown. The danger of pesticides and preservatives in foodstuffs is obvious. For chemical or other action media near the ground are possible, with which the children are in direct contact, such as parquet, carpets, laundry, entry from outside by dogs, etc. They may be the source of contamination with wood preservatives, herbicides, insecticides, mold, soil impregnation, insect pest control, domestic and wild animal infectious material. The harmful intake dose only from the mouth-level breath of infants, who spend years in positions close to these sources, is the smallest amount and exponentially higher than 1, 80 m. Vaccinations with possible adverse reactions to the vaccine or its preservatives, such as mercury, are suspected to cause autism. Autism, chronic fatigue syndrome (CFS) and the variety of gastric diseases and symptoms are still untreatable. (5)

Dr. John Chia found an enterovirus-infected stomach in his son Andrew, a child with chronic fatigue syndrome (CFS). (6) After he succeeded in eliminating the enterovirus infection (i.e., by restoring the stomach's pantothenic acid-CoA capacity from food), Andrew recovered completely (7)

For the treatment of autism / CFS, chronic metabolic deficiency and gastric symptoms, the pantothenic acid-CoA complex of the invention is provided. This remedies the pantothenic acid-CoA uptake deficit caused by gastric problems and prepares the restoration of normal gastric functions.

Patients with Alzheimer's disease, AD, experience tacrine, donepezil, rivastigmine, or galantamine improvement after their administration of acetylcholinesterase inhibitors. (8) Side effects Nausea, vomiting, cramping and diarrhea are contractions of smooth muscle (stomach, intestine, bladder) that may occur especially after a meal. Then the stomach immediately begins to take pantothenic acid CoA from the food. When CoA → acetyl-CoA → acetylcholine augmentation reaches the response threshold of 10 ^{~ 16} g / l in smooth muscle, they contract. The report lacks references to meals before the onset of the reactions and their duration. Pantothenic acid-CoA treatment of AD allows a true variable compensation of acetylcholine deficiency, which avoids when using acetylcholinesterase inhibitors necessarily occurring exhaustion of acetylcholine and improves in existing AD the condition without causing adverse reactions.

Soon after the return of soldiers from Operation Desert Storm of Kuwait and Iraq in 1991, some of the veterans became aware of a number of chronic diseases known as Gulf War syndrome or Gulf War IIIness, which have not been treated to date. ( 9) In some cases, the disease spread to the family, relatives. Chronic Fatigue Syndrome CFS, mental and gastric symptoms, show metabolic performance weakness in the chronic-deficient condition. This weakness is the result of digestive tract disease, which disturbs the stomach's ability to take up pantothenic acid (CoA). Regardless of the type of infection or poisoning that led to damage to the digestive tract, the supply of the pantothenic acid-CoA complex according to the invention improves the CoA → acetyl-CoA balance in the tissue, in the mitochondria, from which feeds the metabolic performance, remedied by gastric Problems caused pantothenic acid-CoA uptake deficiency and prepares the restoration of normal gastric functions.

The agent according to the invention is therefore likewise provided for the treatment of the so-called Gulfwarness and similar diseases.

Various antibiotics, aspirin and other drugs produce "stomach problems", including myasthenia, i. they damage the digestive tract. A mixture or a combination of pantothenic acid CoA with these substances ensures a better long-term tolerance.

For further verification, reference is made to the following observations: In groups one to three and five, natural excess acetylcholine reactions take place after ingestion, experiment four was observed in 1991. Sudden short-acting acetylcholine excess reactions after pantothenic acid CoA dietary intake, cholinergic smooth muscle contractions after ingestion:

1. Baby ^'s when they "spit" after feeding, when the stomach suddenly empties, contracts, and some babies also experience sudden diarrhea. 2. children; often girls, often throw up at or after meals.

3. Primates, monkeys, etc., vomit after eating plenty of food.

4. Operation Desert Storm 1991, Kuwait-Iraq. Thousands of young healthy men and women

Women, soldiers, reported that after taking bromide (PB), an acetylcholinesterase inhibitor, their physique showed adverse reactions ("side effects" of PB including nausea, vomiting, abdominal cramps, diarrhea, increased salivation, sweating, muscle cramps), she had forced excess acetylcholine reactions, cholinergic smooth muscle contractions. (10)

5. The pet dog vomits frequently during or after eating.

Various antibiotics, aspirin and other medicines cause "stomach problems", myasthenic phenomena, damage the stomach's ability to assimilate CoA, and mixing or otherwise combining pantothenic acid analogues with these many substances provides better tolerability.

According to the invention, a dietary supplement comprising 85-99% pantothenic acid, its precursors, its derivatives and / or its salts and optionally further additives is provided. Preference is given to using calcium pantothenate as the salt. In a further preferred embodiment, pantothenic acid is used for the pantothenic acid. It is manufactured by Daiichi Pharmaceutical Co., Ltd., as Pantesin.

The invention furthermore relates to an agent for preparing a preparation for alleviating metabolic weakness, comprising 85-99% pantothenic acid and / or its salts and optionally further additives, preference being given to using calcium pantothenate and / or pantethine as the salt.

In a preferred embodiment, the agent according to the invention is provided in an enteric preparation.

Other additives include vitamins, amino acids, fatty acids, phospholipids, coenzymes, trace elements, bioactive substances, minerals and / or gingko used. The agent is used to treat metabolic performance weakness. Furthermore, it is suitable for the treatment of chronic fatigue, lack of strength, respiratory weakness, for improving mental and physical life and health conditions, in particular emotion, creativity, memory, regeneration, activity, sexuality, exercise, work, endurance and / or convalescence.

Especially in the phenomena of changing mental and physical life and health, in emotion, sexuality, creativity, memory, activity, movement, work, perseverance, fatigue, recovery, exhaustion, illness, convalescence, infirmity, variants of life are formed in his Metabolic performance, its metabolic performance weakness. The most mentally-sexual complex, Allen's Most Insensitive, suffers first loss of ability and endurance due to metabolic weakness.

Thus, the agent is suitable for the treatment of periodic female debility and migraine as well as for the treatment of pantothenic acid-CoA deficiency, especially due to age.

Mitochondrial dysfunction as a result of long-lasting CoA deficiency, caused by bacterial, viral, chemical damage to the digestive tract, as a result of impaired O ² uptake and O ² transmission and / or overloading, leads to disintegration of the metabolism.

Balancing the lack of CoA by adding pantothenic acid CoA in the proposed composition does more than just compensate for current deficiency

In the long run, compensation by means of supply eliminates the lack of process substance in the metabolism and eliminates fatal malfunctions, incorrect reactions, faulty control, incorrect degradation, undesirable developments, and finally diseases in the organism:

Cancer,

Immunodeficiency,

Autoimmune reactions, inflammation, rheumatic diseases, Heart failure

Allergy, fever,

Joint wear, arthritis, arthritis

Asthma, male - female fertility disorder, sperm immobility,

depressions

Burnout syndrome,

Reduction of efficiency, concentration, exhaustion

Respiratory dysfunction, impaired O ² utilization under contaminated respiratory air,

Effects of ionizing radiation,

Effects of electromagnetic fields on gastric function

Hair diseases.

Therefore, the inventive agent in further embodiments of the

Prevention and / or concomitant treatment of cancer, immunodeficiency,

Autoimmune reactions, inflammation and / or rheumatic diseases suitable. It is also applicable to cardiac output weakness, allergies, arthritis,

Joint wear, arthrosis, asthma, male, female fertility disorder,

Spermienimmobilität. In another embodiment, it is for the prevention and treatment of depression, burnout syndrome, degradation of performance and / or concentration, fatigue, deterioration of endurance and

Memory, respiratory depression, impaired O ² recovery under stress

Breathing air, fever, effects of ionizing radiation, effects of electromagnetic

Fields suitable for gastric functions and / or hair disorders.

It is also useful for the treatment of erectile dysfunction, abnormal sensations in the sexual area, malfunctioning perception functions, delusions of childish problems, developmental disorders,

Behavioral disorders, inflammation, erosive joint diseases,

Labor weakness, Restless Legs Syndrome (RLS), incontinence, mental health problems and / or migraines. It is also suitable for improving the tolerability of stomach-damaging drugs.

In a particular embodiment, it is useful in the treatment and prevention of damage caused by the ingestion of pyridostigmine bromide and / or in the treatment of Gulf War disease. In a further embodiment, the agent according to the invention is suitable for the treatment of tinitus. Tinitus also develops out of a metabolic power weakness and is one of the first signs of further and serious sequelae.

It has also been found that the efficacy of insulin administration in the treatment of diabetes mellitus can be significantly improved by the combined use with the agent according to the invention. The effect of insulin is strengthened and lasts longer. The agent should therefore also be used to treat diabetes in combination with insulin therapy.

In another embodiment, it is to be used to improve the condition of Alzheimer's (AD) patients.

It is also to be used to assist in the treatment of infections, infectious diseases, fever, HIV, carcinoma and / or treatment in psychiatry and to prevent and assist the treatment of autism and / or autistic disorders.

It improves gastric function and improves the effects of oral antibiotics.

Balancing the CoADAcetyl-CoA deficiency in mitochondria by adding the agent requires time to "replenish" the agent pool to achieve regeneration and improvement, which is similar to convalescence after a severe illness, when the strength status from own CoA uptake is slow In case of impaired CoA uptake under gastric problems, the "replenishment" by delivery is more protracted.

With deep-maturing metabolic weakness, immediate improvements are not expected. After initial improvements, weeks can go by to lasting success. The remedy is in variable amounts, the disease state appropriate to use in single doses of 1 g to over 10 g several times a day, before, at or after meals.

The occurrence of side effects, adverse reactions in smooth muscles, marked the optimum intake, the remedy is easy to reduce.

Possible applications for the agent are oral, buccal, sublingual, anal, intramuscular, intravenous or intra-arterial administration, other possibilities are also conceivable.

Preferably, the agent is applied as a priem, a chewable tablet, jelly, pudding, lozenge, or insole.

The uptake of the agent takes place via contact with the oral mucosa. The agent is preferably fixed in a predominantly edible carrier, also flavored, in any suitable form. The carrier can be made of jelly, fruit gum, starch, vegetable, animal substance or inert material, e.g. consist of a tissue bag. The preparation is portioned and permanently packed.

Ingestion of the agent via oral delivery:

In known manner, the agent is portioned in any form and added to the enteric state. For instance, in rice grain lentils, pea bean size, the agent may then be used loosely with any liquid carrier.

Improved handling and dosage can be ensured by packaged preparations. These contain the enteric preparation in a liquid carrier, e.g. Pudding, soup, dairy, ready for application or separately from the mixture before use in various concentrations. In a preferred embodiment, the provision / use of the agent takes place in prefabricated battery packs for weeks / month treatment duration.

Another particular embodiment is characterized by admixing pantothenic acid, its precursors, its derivatives and / or its salts to beverages. Suitable for this are soft drinks, especially so-called functional drinks, wellness drinks or power drinks, which are enjoying increasing popularity in this day and age. Thus, the health-promoting properties of the composition according to the invention can be easily used in everyday life. In addition, it provides an improved energy drink, which naturally increases the metabolic performance and promotes health. The active content of the beverage preferably consists of small granular enteric supplements of pantothenic acid, its precursors, its derivatives and / or its salts.

Likewise provided by the invention is a process for the preparation of the dietary supplement and the agent.

The invention will be explained in more detail below with reference to exemplary embodiments.

Embodiment 1

Babies like to "spit" after feeding (a cholinergic reaction). From the milk pulp lining, the stomach immediately takes pantothenic acid CoA into the metabolism. If acetylcholine production in the (smooth) gastric muscle exceeds the reaction threshold of 10 ^"16 g / L in the muscle, some babies have such high CoA capacity that they may experience sudden diarrhea in addition to gastric contraction. mostly girls, at or after eating.

Embodiment 2

In the war in Iraq in 1991, 250,000 to 300,000 US and coalition soldiers took the active ingredient pyridostigmine bromide (PB) as protection against Iraqi poison gas attacks. Young healthy men and women, soldiers, reported on the "self-experiment" in which, after taking 30 mg of pyridostigmine bromide, an acetylcholinesterase inhibitor, their physique reacted adversely; they had accelerated acetylcholine release, recognizable by the contraction of smooth muscle, in the strongest form as nausea, vomiting, stomach spasm, diarrhea, urgency, increased salivation, sweating, and muscle spasm. These effects occurred shortly after taking the Tablets on and disappeared with discontinuation of medication.

Many of the soldiers had taken the PB tablet to eat. The pantothenic acid CoA uptake of the stomach from the diet was high when PB inhibited acetylcholinesterase. Massive acetylcholine proliferation occurred with acetylcholine production from food forced stomach with the described contraction effects on the stomach intestine, bladder, glands. The relationship of ACH accumulation augmentation with food intake is unknown (9) (10).

Embodiment 3

Primates, monkeys like, vomit after eating plenty of food. The pet dog also vomits often after eating. The dependence of gastric contraction on previously ingested feed is evident.

All features set forth in the foregoing description and claims may be relevant to the realization of the invention in its various forms both individually and in any combination thereof.

literature

1) Nicolson, G.L. Ph. D, Lipid Replacement as to Adjunct to Therapy for Chronic Fatigue, Anti-Aging and Restoration of Mitochondrial Function The Journal of the American Nutraceutical Association Vol. 1, 2001

2) Nicolson, G.L. Ph. D Chronic Fatigue, Aging, Mitochondrial Function and Nutritional Supplements. Townsend Letter for Doctors and Patients, Ju Iy, 03

3) wedge, uta, key function of mitochondria in the pathogenesis of Alzheimer's dementia. Dissertation, Frankfurt am Main 2005

4) dtv Atlas zur Biologie 2. Aufl.1969, Bd 2, p.375

The tetanic muscle under curare; Acetylcholine, the natural excitement transmitter from the nerve to the muscle, acts on striped muscles in concentrations around 10 ^{~ 6} g / I, on smooth already at 10 ^"16 g / I.

5) J. Madeleine Nash The Secrets of Autism, The Number of Children Diagnosed with Autism and Asperger's in the U.S.. is exploding. Why? FROM THE MAY 6, 2002 ISSUE OF TIME MAGAZINE;

6) Chia, John kai-sheng and Chia, Andrew Y.

Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. J. Clin. Pathol. Published Online First: 13 September 2007.

7) Sept.13. 2007 HealthDayNews womans Health.gov. The Federal Government Source for Woman's Health Information.

8) Cummings, J. L. Treatment of Alzheimers disease. Dementia, VoI 3, No 4,

9) Research Advisory Committee on Guild War Veterans' Illnesses.

Guild War Illness and the Health of War War Veterans Additional Clinical and Research Findings D 263, Assessment of Gastrointestinal Symptoms and Conditions. U.S. Department of Veterans Affairs Washington, D.C. 2008

10) Keeler, J.R. Hurst C.G. and Thin A.M. Pyridostigmine used as a nerve agent pretreatment under wartime conditions, Jama Vol. 266 No.5, August 7

11) Myhill, S. Booth N, E. McLaren-Howard, J. Chronic Fatigue Syndrome and Mitochondrial Dysfunction Int J Clin Exp Med (2009) 2, 1-16

12) Bains, W. Treating chronic fatigue states as a disease of the regulation of energy metabolism. edical hypothesis 2008 Delta G Ltd, 37 The Moor, Melbourne, Royston, Herts SG8 6ED, UK 13) EU Food Committee SFC 1992, 2002. Food and Nutrition Board (USA), IMO 2000. EVM (UK) 2003

Claims

claims

1. Nutritional supplement comprising 85-99% pantothenic acid, its precursors, their derivatives and / or their salts and optionally further additives.

2. Composition for the preparation of a preparation for the removal of metabolic weakness including 85-99% pantothenic acid and / or its salts and optionally further additives.

3. Composition according to claim 2 for the treatment of metabolic weakness and related symptoms.

4. Composition according to one of claims 2-3 for the treatment of chronic fatigue and weakness, respiratory depression, age-related pantothenic acid deficiency, for the treatment and prevention of damage caused by the ingestion of pyridostigmine bromide, to improve mental and physical life and health conditions, especially emotion, creativity , Memory, regeneration, activity, sexuality, exercise, work, stamina and / or convalescence.

5. A composition according to any one of claims 2-Λ for the treatment of periodic female debility, migraine, Gulf War disease, Gulf War disease, tinitus, diabetes in combination with insulin therapy, symptoms of poisoning with pesticides / insecticides of damage and intoxication, especially in agriculture, Improving the tolerability of stomach-damaging drugs, improving the condition of Alzheimer's (AD) patients, reducing the side effects associated with ACHE inhibitors in Alzheimer's (AD) patients, treating erectile dysfunction, sexual abnormalities, impaired cognition, delusions, Childish problems, developmental disorders, behavioral disorders, inflammation, rheumatic diseases, attrition Illnesses, labor problems, Restless Legs Syndrome (RLS), incontinence, and / or mental health problems.

6. A composition according to any one of claims 2-5 for the support of the treatment of infections, infectious diseases, fever, HIV, carcinomas, treatment in psychiatry, for the prevention and support of the treatment of autism and / or autistic disorders and / or to improve the Gastric function and the improvement in the effect of oral antibiotics.

7. Composition according to one of claims 2-6 for the prevention and / or concomitant treatment of cancer, immunodeficiency, autoimmune reactions, cardiac output weakness, allergies, arthritis, joint wear, osteoarthritis, asthma, male and female fertility improvement, improvement of sperm mobility, depression, burnout syndrome , Degradation of performance and / or concentration, deterioration of endurance and memory, impaired O ² utilization under stressed breath, effects of ionizing radiation, effects of electromagnetic fields on gastric function and / or hair disorders.

8. A composition according to any one of claims 1-7, wherein the agent is oral, buccal, sublingual, anal, i. m, administered intravenously or intraarterially.

9. Composition according to one of claims 1- 8, characterized in that it is fixed on a support.

10. A process for the preparation of a dietary supplement according to claim 1.

11.A method for producing a composition according to claim 2.

12. Use of an agent according to claim 1 for improving the metabolic performance and associated symptoms and / or diseases.

13. Use of an agent according to claim 2 for improving metabolic performance and associated symptoms and / or diseases.

14. Dietary supplement according to one of claim 1, for improving the metabolic performance.

15. A method for the treatment of metabolic performance weakness, characterized in that large daily doses of pantothenic acid, their precursors, their derivatives and / or their salts and optionally other additives are included.